ClinicalTrials.gg
CompletedNCT06624072Updated Jan 8, 2026Results posted

A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food

A Phase 1 interventional study of Nerandomilast 18 mg - adult formulation and Nerandomilast 1 mg - paediatric formulation in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main objective of this trial is to investigate two different formulations of nerandomilast and the effect of food on the pharmacokinetics of the new formulation following oral administration.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 55 years (inclusive)
  • (BMI) of 18.5 to 29.9 kg/m² (inclusive)
  • Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Nerandomilast (18 mg) in treatment sequence R-T1-T2

    Participants first received a single oral dose of 1 tablet of 18 milligrams (mg) nerandomilast adult formulation in the fasted state (Reference treatment, R), followed by a single oral dose of 18 tablets of 1 mg nerandomilast pediatric formulation in the fasted state (Treatment, T1), and then 18 tablets of 1 mg of nerandomilast pediatric formulation in the fed state as a single oral dose (Treatment, T2). Treatments were separated by a wash-out period of at least 7 days and treatments were taken with 240 mL of water after an overnight fast of at least 10 hours (hrs) for R and T1, or after a high-fat, high-calorie breakfast for T2.

    Drug: Nerandomilast 18 mg - adult formulation · Drug: Nerandomilast 1 mg - paediatric formulation

  • Experimental
    Nerandomilast (18 mg) in treatment sequence T1-T2-R

    Participants first received a single oral dose of 18 tablets of 1 mg nerandomilast pediatric formulation in the fasted state (T1), followed by a single oral dose of 18 tablets of 1 mg nerandomilast pediatric formulation in the fed state (T2), and then a single oral dose of 18 mg of nerandomilast adult formulation in the fasted state (R). Treatments were separated by a wash-out period of at least 7 days and treatments were taken with 240 mL of water after an overnight fast of at least 10 hrs for R and T1, or after a high-fat, high-calorie breakfast for T2.

    Drug: Nerandomilast 18 mg - adult formulation · Drug: Nerandomilast 1 mg - paediatric formulation

  • Experimental
    Nerandomilast (18 mg) in treatment sequence T2-R-T1

    Participants first received a single oral dose of 18 tablets of 1 mg nerandomilast pediatric formulation in the fed state (T2), followed by a single oral dose of 18 mg of nerandomilast adult formulation in the fasted state (R), and then a single oral dose of 18 tablets of 1 mg nerandomilast pediatric formulation in the fasted state (T1). Treatments were separated by a wash-out period of at least 7 days and treatments were taken with 240 mL of water after an overnight fast of at least 10 hrs for R and T1, or after a high-fat, high-calorie breakfast for T2.

    Drug: Nerandomilast 18 mg - adult formulation · Drug: Nerandomilast 1 mg - paediatric formulation

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-tz (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Treatment T1 vs Reference R

    AUC0-tz (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 to the last quantifiable data point) for Treatment T1 vs Reference R is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% confidence interval (CI).

    Time frame: Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.

  2. AUC0-tz (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Treatment T2 vs T1

    AUC0-tz (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 to the last quantifiable data point) for Treatment T2 vs T1 is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.

    Time frame: Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.

  3. Cmax (Maximum Measured Concentration of Nerandomilast in Plasma) for Treatment T1 vs Reference R

    Cmax (maximum measured concentration of nerandomilast in plasma) for Treatment T1 vs Reference R is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.

    Time frame: Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.

  4. Cmax (Maximum Measured Concentration of Nerandomilast in Plasma) for Treatment T2 vs T1

    Cmax (maximum measured concentration of nerandomilast in plasma) for Treatment T2 vs T1 is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.

    Time frame: Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.

Secondary outcomes

  1. AUC0-∞ (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Treatment T1 vs Reference R

    AUC0-∞ (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 extrapolated to infinity) for Treatment T1 vs Reference R is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.

    Time frame: Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.

  2. AUC0-∞ (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Treatment T2 vs T1

    AUC0-∞ (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 extrapolated to infinity) for Treatment T2 vs T1 is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.

    Time frame: Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.

07

Results

Posted Jan 8, 2026

Participant flow

This trial was an open-label, single dose, 3-way crossover design. Subjects were randomly allocated to one of 3 treatment sequences. Each subject participated in 3 treatment periods, receiving a single dose in each, with a washout period of at least 7 days between treatments.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneNerandomilast (18 mg) in Treatment Sequence R-T1-T2Nerandomilast (18 mg) in Treatment Sequence T1-T2-RNerandomilast (18 mg) in Treatment Sequence T2-R-T1
Started555
Completed555
Not completed000
Washout Period 1 (7 days)
Participant flow — Washout Period 1 (7 days)
MilestoneNerandomilast (18 mg) in Treatment Sequence R-T1-T2Nerandomilast (18 mg) in Treatment Sequence T1-T2-RNerandomilast (18 mg) in Treatment Sequence T2-R-T1
Started555
Completed554
Not completed001
Withdrew: Adverse event001
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneNerandomilast (18 mg) in Treatment Sequence R-T1-T2Nerandomilast (18 mg) in Treatment Sequence T1-T2-RNerandomilast (18 mg) in Treatment Sequence T2-R-T1
Started554
Completed554
Not completed000
Washout Period 2 (7 days)
Participant flow — Washout Period 2 (7 days)
MilestoneNerandomilast (18 mg) in Treatment Sequence R-T1-T2Nerandomilast (18 mg) in Treatment Sequence T1-T2-RNerandomilast (18 mg) in Treatment Sequence T2-R-T1
Started555
Completed555
Not completed000
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneNerandomilast (18 mg) in Treatment Sequence R-T1-T2Nerandomilast (18 mg) in Treatment Sequence T1-T2-RNerandomilast (18 mg) in Treatment Sequence T2-R-T1
Started555
Completed555
Not completed000

Outcome measures

PrimaryAUC0-tz (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Treatment T1 vs Reference R

AUC0-tz (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 to the last quantifiable data point) for Treatment T1 vs Reference R is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% confidence interval (CI).

Time frame:
Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.
Reported as:
Geometric least squares mean · hours*nanomoles/Liter (h·nmol/L)
AUC0-tz (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Treatment T1 vs Reference R
hours*nanomoles/Liter (h·nmol/L)Nerandomilast 18 mg Pediatric (Ped) Fasted State (Treatment T1)Nerandomilast 18 mg Adult Fasted State (Reference R)
AUC0-tz (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Treatment T1 vs Reference R2732.81 ± NA2647.2 ± NA
Statistical analysis
  • Nerandomilast 18 mg Pediatric (Ped) Fasted State (Treatment T1) vs Nerandomilast 18 mg Adult Fasted State (Reference R) · Ratio of adjusted geometric means (t1/r): 103.23 · 90% CI 97.31 to 109.52Ratio as percentage \[%\] Intra-individual geometric coefficient of variation (gCV) = 8.7%.
PrimaryAUC0-tz (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Treatment T2 vs T1

AUC0-tz (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 to the last quantifiable data point) for Treatment T2 vs T1 is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.

Time frame:
Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.
Reported as:
Geometric least squares mean · hours*nanomoles/Liter (h·nmol/L)
AUC0-tz (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Treatment T2 vs T1
hours*nanomoles/Liter (h·nmol/L)Nerandomilast 18 mg Ped Fed State (Treatment T2)Nerandomilast 18 mg Ped Fasted State (Treatment T1)
AUC0-tz (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Treatment T2 vs T12611.55 ± NA2732.81 ± NA
Statistical analysis
  • Nerandomilast 18 mg Ped Fed State (Treatment T2) vs Nerandomilast 18 mg Ped Fasted State (Treatment T1) · Ratio of adjusted geometric means, t2/t1: 95.56 · 90% CI 89.37 to 102.18Ratio as percentage \[%\] Intra-individual geometric coefficient of variation (gCV) = 10.3%.
PrimaryCmax (Maximum Measured Concentration of Nerandomilast in Plasma) for Treatment T1 vs Reference R

Cmax (maximum measured concentration of nerandomilast in plasma) for Treatment T1 vs Reference R is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.

Time frame:
Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.
Reported as:
Geometric least squares mean · nanomoles/Liter (nmol/L)
Cmax (Maximum Measured Concentration of Nerandomilast in Plasma) for Treatment T1 vs Reference R
nanomoles/Liter (nmol/L)Nerandomilast 18 mg Ped Fasted State (Treatment T1)Nerandomilast 18 mg Adult Fasted State (Reference R)
Cmax (Maximum Measured Concentration of Nerandomilast in Plasma) for Treatment T1 vs Reference R501.74 ± NA480.85 ± NA
Statistical analysis
  • Nerandomilast 18 mg Ped Fasted State (Treatment T1) vs Nerandomilast 18 mg Adult Fasted State (Reference R) · Ratio of adjusted geometric means, t1/r: 104.34 · 90% CI 91.00 to 119.65Ratio as percentage \[%\] Intra-individual geometric coefficient of variation (gCV) = 20.4%.
PrimaryCmax (Maximum Measured Concentration of Nerandomilast in Plasma) for Treatment T2 vs T1

Cmax (maximum measured concentration of nerandomilast in plasma) for Treatment T2 vs T1 is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.

Time frame:
Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.
Reported as:
Geometric least squares mean · nanomoles/Liter (nmol/L)
Cmax (Maximum Measured Concentration of Nerandomilast in Plasma) for Treatment T2 vs T1
nanomoles/Liter (nmol/L)Nerandomilast 18 mg Ped Fed State (Treatment T2)Nerandomilast 18 mg Ped Fasted State (Treatment T1)
Cmax (Maximum Measured Concentration of Nerandomilast in Plasma) for Treatment T2 vs T1344.76 ± NA501.74 ± NA
Statistical analysis
  • Nerandomilast 18 mg Ped Fed State (Treatment T2) vs Nerandomilast 18 mg Ped Fasted State (Treatment T1) · Ratio of adjusted geometric means, t2/t1: 68.71 · 90% CI 61.23 to 77.11Ratio as percentage \[%\] Intra-individual geometric coefficient of variation (gCV) = 17.9%.
SecondaryAUC0-∞ (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Treatment T1 vs Reference R

AUC0-∞ (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 extrapolated to infinity) for Treatment T1 vs Reference R is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.

Time frame:
Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.
Reported as:
Geometric least squares mean · hours*nanomoles/Liter (h·nmol/L)
AUC0-∞ (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Treatment T1 vs Reference R
hours*nanomoles/Liter (h·nmol/L)Nerandomilast 18 mg Pediatric (Ped) Fasted State (Treatment T1)Nerandomilast 18 mg Adult Fasted State (Reference R)
AUC0-∞ (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Treatment T1 vs Reference R2748.78 ± NA2667.20 ± NA
Statistical analysis
  • Nerandomilast 18 mg Pediatric (Ped) Fasted State (Treatment T1) vs Nerandomilast 18 mg Adult Fasted State (Reference R) · Ratio of adjusted geometric means, t1/r: 103.06 · 90% CI 97.22 to 109.25Ratio as percentage \[%\] Intra-individual geometric coefficient of variation (gCV) = 8.6%.
SecondaryAUC0-∞ (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Treatment T2 vs T1

AUC0-∞ (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 extrapolated to infinity) for Treatment T2 vs T1 is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.

Time frame:
Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.
Reported as:
Geometric least squares mean · hours*nanomoles/Liter (h·nmol/L)
AUC0-∞ (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Treatment T2 vs T1
hours*nanomoles/Liter (h·nmol/L)Nerandomilast 18 mg Ped Fed State (Treatment T2)Nerandomilast 18 mg Ped Fasted State (Treatment T1)
AUC0-∞ (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Treatment T2 vs T12631.39 ± NA2748.78 ± NA
Statistical analysis
  • Nerandomilast 18 mg Ped Fed State (Treatment T2) vs Nerandomilast 18 mg Ped Fasted State (Treatment T1) · Ratio of adjusted geometric means, t2/t1: 95.73 · 90% CI 89.47 to 102.42Ratio as percentage \[%\] Intra-individual geometric coefficient of variation (gCV) = 10.4%.

Adverse events

Collected over Adverse events: From intake of trial medication till end of the residual effect period (REP), up to 7 days for each treatment. All-Cause Mortality: Up to 7 days (REP) for each treatment (R, T1, T2), then follow-up (13 days), up to a total of 34 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nerandomilast 18 mg Adult Fasted State (Reference R)0/14 (0%)0/14 (0%)6/14 (42.9%)
Nerandomilast 18 mg Ped Fasted State (Treatment T1)0/15 (0%)0/15 (0%)11/15 (73.3%)
Nerandomilast 18 mg Ped Fed State (Treatment T2)0/15 (0%)0/15 (0%)7/15 (46.7%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventNerandomilast 18 mg Adult Fasted State (Reference R)Nerandomilast 18 mg Ped Fasted State (Treatment T1)Nerandomilast 18 mg Ped Fed State (Treatment T2)
HeadacheNervous system disorders4/147/156/15
NauseaGastrointestinal disorders2/142/152/15
DizzinessNervous system disorders2/140/150/15
Abdominal distensionGastrointestinal disorders0/142/151/15
VomitingGastrointestinal disorders0/140/152/15
Pain in extremityMusculoskeletal and connective tissue disorders1/142/150/15
Skin lesionSkin and subcutaneous tissue disorders0/142/150/15
ConstipationGastrointestinal disorders1/140/150/15
FatigueGeneral disorders1/140/150/15
MyalgiaMusculoskeletal and connective tissue disorders1/140/150/15

Baseline characteristics

Treated set (TS): The treated set included all subjects who were treated with at least one dose of trial drug. The number of subjects reported in each arm represents the number of subjects who took the first treatment in the respective sequence.

Age, Continuous
Age, Continuous(Years)Nerandomilast (18 mg) in Treatment Sequence R-T1-T2Nerandomilast (18 mg) in Treatment Sequence T1-T2-RNerandomilast (18 mg) in Treatment Sequence T2-R-T1Total
Mean40.2 ± 10.537.8 ± 10.139.8 ± 8.639.3 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Nerandomilast (18 mg) in Treatment Sequence R-T1-T2Nerandomilast (18 mg) in Treatment Sequence T1-T2-RNerandomilast (18 mg) in Treatment Sequence T2-R-T1Total
Female43512
Male1203
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nerandomilast (18 mg) in Treatment Sequence R-T1-T2Nerandomilast (18 mg) in Treatment Sequence T1-T2-RNerandomilast (18 mg) in Treatment Sequence T2-R-T1Total
Hispanic or Latino0000
Not Hispanic or Latino55515
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nerandomilast (18 mg) in Treatment Sequence R-T1-T2Nerandomilast (18 mg) in Treatment Sequence T1-T2-RNerandomilast (18 mg) in Treatment Sequence T2-R-T1Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White55515
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Nov 2024, 1 month.

Results were first posted in Jan 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Oct 2, 2024
StartActual
Oct 15, 2024
Primary completionActual
Nov 22, 2024
CompletionActual
Nov 30, 2024
Results first posted
Jan 8, 2026
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06624072
Responsible party
Sponsor
First posted
Oct 2, 2024
Start date
Oct 15, 2024
Primary completion
Nov 22, 2024
Completion
Nov 30, 2024
Results posted
Jan 8, 2026
Last update
Jan 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion